# A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer

Source: https://onco.cc/trials/nct05491512/  
OnCo record `nct05491512` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of F-MISO (JBS-003) run by Memorial Sloan Kettering Cancer Center, now recruiting.

## Summary

A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer is a phase 2 interventional study registered as NCT05491512 by Memorial Sloan Kettering Cancer Center, with 121 participants planned, started 2022-08-04. Conditions recorded: HPV, Throat Cancer, Oropharyngeal Carcinoma, Oropharyngeal Cancer and Human Papilloma Virus. Interventions recorded: 18 F-FMISO PET/CT, Radiation, Cisplatin, Carboplatin and 5-fluorouracil.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05491512
- Phase: 2
- Setting: Major Radiation Dose De-Escalation Concurrent With Chemotherapy for Human Papilloma Virus Associated Oropharyngeal Carcinoma
- Sponsor: Memorial Sloan Kettering Cancer Center
- Enrolled: 121

## Sources

- ClinicalTrials.gov NCT05491512: https://clinicaltrials.gov/study/NCT05491512

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Oropharyngeal cancer (tonsil and base of tongue)](https://onco.cc/cancers/oropharyngeal-cancer/)
- drugs: [F-MISO (JBS-003)](https://onco.cc/drugs/jbs-003/)
- companies: [Juniper Biosciences](https://onco.cc/companies/juniper-biosciences/)

---
JSON: https://onco.cc/api/v1/entities/nct05491512.json